Longitudinal Study of Helium-3 and Xenon-129 Magnetic Resonance Imaging
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorDr. Grace Parraga
About this trial
Subjects male and female aged 50-85 with a clinical diagnosis of chronic obstructive pulmonary disease (COPD) or Bronchiectasis, or those with ≥ 10 pack/years smoking history will be imaged with CT and MRI for the development of tools to quantify and validate longitudinal in vivo magnetic resonance imaging phenotypes of COPD and Bronchiectasis.
Eligibility criteria
Qualifiers
Subjects male and female aged 50-85 with either A) a clinical diagnosis of COPD or Bronchiectais or B) >10 pack/year smoking history
Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent
Subject must be able to perform a breathhold for 16s.
Subject is judged to be in otherwise stable health on the basis of medical history
Disqualifiers
Patient is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material.
Subject has a daytime room air oxygen saturation <90% while lying supine.
Patient is unable to perform spirometry or plethysmography maneuvers
Patient is pregnant
Trial design
Treatments tested in this trial
- Hyperpolarized Helium MRI
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Dr. Grace Parraga
Lead sponsor
University of Western Ontario, Canada
Sponsor institution
London Health Sciences Centre
Collaborator
Source ClinicalTrials.gov